3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Breast Neoplasms
1
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
1
Interventions
pembrolizumab
44
Carboplatin
35
Paclitaxel
27
Specimen Handling
18
Cyclophosphamide
16
Capecitabine
16
Magnetic Resonance Spectroscopy
14
sacituzumab govitecan
13
Gemcitabine
13
Taxes
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
Doxorubicin
8
olaparib
7
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Fulvestrant
4
Epirubicin
4
Bevacizumab
4
veliparib
3
famitinib
3
abemaciclib
3
Vinorelbine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
fluzoparib
×
90 days
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled